SHR3680
SHR3680 is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 33.3%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
3
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
33.3%
1 of 3 finished
66.7%
2 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Clinical Trials (9)
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9